Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2007

View Archived Issues

Multiple studies of SCH-527123 in healthy subjects reported

Phase III, other data on bazedoxifene presented

Snapshots of recent in vitro and pharmacokinetic studies of ceftaroline

NeuroSearch seeks approval in Europe to commence phase III trials with ACR-16

(R)-(+) isomer of zileuton enters clinical trials

Not approvable letter assigned for expanded indication for Frova

Trophos begins patient enrollment for TRO-19622 SMA trial

DiaMedica reports promising phase II results with DM-71 for type 2 diabetes

Primary endpoint not reached in phase IIb trial of ANX-510

One-year treatment with tesamorelin shows promise in phase III trial

FDA approves SymlinPen device and issues not approvable letter for expanded Symlin indication

Kyorin launches bronchial asthma treatment for young children

Preclinical antidiabetic activity of Chinese herbal medicinal compound DC-250188

Preclinical profile of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic

Topical nerve growth factor relieves dry eye symptoms in vivo

Recent AstraZeneca patents describe new antiasthmatic agents

Novel coagulation factor VIIa inhibitors emerge from Bristol-Myers Squibb R&D

GlaxoSmithKline discovers novel antianemic agents

Phase II studies show activity of SNS-595 in lung cancer

Axcan licenses rights to Cx-401 for perianal fistulas

FASgen achieves significant milestone in cancer drug program

Isis grants rights to two diabetes drugs to Ortho-McNeil

Newron initiates phase II studies for ralfinamide in post-surgical pain

OSI and Aveo collaborate on oncology drug discovery program

Daiichi Sankyo seeks approval of combination hypertension candidate in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...